Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Economic Evaluation of New Drugs Important: Dr Matsutani of HPB
September 26, 2005
- Discount Rates for Catheters, Pacemakers Average 17%: Survey
September 26, 2005
- Staff Members Must Be Increased at ELD and PMDA: New PFSB Director General
September 26, 2005
- MEDICAL DEVICE NEWS IN BRIEF
September 26, 2005
- Meeting of CDFS's Department on Drugs
September 26, 2005
- NEW PRODUCTS
September 26, 2005
- JMA's Involvement in Recommendation of Reps. of Hosp. Org. Necessary: Korosho
September 26, 2005
- MARKET SURVEY
September 26, 2005
- REGULATORY NEWS IN BRIEF
September 26, 2005
- GENERICS NEWS IN BRIEF
September 26, 2005
- JPLA LECTURE
September 26, 2005
- Innovative Drugs Should Be Valued More Highly: Mr Otsuji
September 26, 2005
- Taisho Toyama Aims at \120 Mil. Sales per MR ASAP: Mr Uehara of Taisho
September 26, 2005
- Mr Fujii, New President of QTJ, Introduced by Dr Gillings
September 26, 2005
- Alfresa HD, Meisyo to Merge in April 2006
September 26, 2005
- BUSINESS NEWS IN BRIEF
September 26, 2005
- Goodrug to Begin Internet Sale of Generics on Oct. 1
September 19, 2005
- Incidence of Abnormality Rose in All Age Brackets in 2004: Health Examinations
September 19, 2005
- Kyorin to Back Up Toyo Pharmar in Earnest
September 19, 2005
- Kenporen Calls For Reductions in Medical Fees
September 19, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…